Short-term clinical response to anti-TNFs at 10 weeks after anti-TNF initiation was found to be significantly worse in elderly IBD patients (68% vs. 89%; p < 0.001), meaning that the probability of ceasing treatment during the follow-up period (regardless of the reason) was higher; however, when primary nonresponse was excluded, this proportion was similar between the two groups. The gene discussed is TNF; the disease is inflammatory bowel disease.